 DARTMOUTH, Nova Scotia--BUSINESS WIRE--IMV Inc. Nasdaq: IMV; TSX: IMV the Company, a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today reported update on the development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-CoV-2. We are encouraged by the data generated thus far. Results are consistent with the mechanism of action of 